Critical Insights From Pacific Biosciences Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Pacific Biosciences (NASDAQ:PACB) has received a range of analyst ratings over the past three months, with a notable decline in the average 12-month price target from $8.00 to $3.64. Analysts have predominantly lowered their ratings and price targets, reflecting a bearish sentiment. The company's financial metrics, including a decline in revenue and high debt-to-equity ratio, indicate potential challenges ahead.
June 03, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Pacific Biosciences has seen a significant decline in analyst ratings and price targets, with the average 12-month price target dropping from $8.00 to $3.64. The company's financial metrics, including a decline in revenue and a high debt-to-equity ratio, suggest potential challenges ahead.
The majority of analysts have lowered their ratings and price targets for PACB, indicating a bearish sentiment. The company's financial metrics, such as declining revenue and a high debt-to-equity ratio, further support the negative outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100